Science Explorer Back to mapMap
Institution · Dutch Cancer Society

Most cited papers from Dutch Cancer Society

What are the most cited papers from Dutch Cancer Society?

The most cited paper from Dutch Cancer Society is "A Gene-Expression Signature as a Predictor of Survival in Breast Cancer" (Marc J. van de Vijver et al., 2002), with 6,562 citations. Next come "International network of cancer genome projects" (2,439) and "Defining ‘T cell exhaustion’" (1,669).

Showing 50 of 60 papers. Every paper with more than 256 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 A Gene-Expression Signature as a Predictor of Survival in Breast Cancer Marc J. van de Vijver et al. · New England Journal of Medicine Open access 18 Dec 2002 6,562
2 International network of cancer genome projects Jennifer L. Jennings et al. · Nature Open access256 authors 13 Apr 2010 2,439
3 Defining ‘T cell exhaustion’ Christian U. Blank, W. Nicholas Haining, Werner Held et al. · Nature reviews. Immunology ReviewOpen access 30 Sep 2019 1,669
4 Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial Antoni Ribas et al. · The Lancet Oncology Open access 24 Jun 2015 1,581
5 Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers Myriam Chalabi et al. · Nature Medicine Open access Apr 2020 1,437
6 Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial Georgina Venetia Long et al. · The Lancet 31 May 2015 1,419
7 Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial Ian Robert Judson, Jaap Verweij, Hans A. J. Gelderblom et al. · The Lancet Oncology Open access 5 Mar 2014 1,195
8 Direct detection of early-stage cancers using circulating tumor DNA Jillian A. Phallen et al. · Science Translational Medicine Open access 16 Aug 2017 1,185
9 Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study Caroline Robert, Antoni Ribas, Jacob Schachter et al. · The Lancet Oncology Open access 22 Jul 2019 1,179
10 Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study Alison J. Rodger et al. · The Lancet Open access189 authors 2 May 2019 1,029
11 Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project Milena Sant, Claudia Allemani, Carmen Ţereanu et al. · Blood Open access 27 Jul 2010 978
12 Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal Ino de Bruijn et al. · Cancer Research Open access 5 Sep 2023 918
13 Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients Salo Ooft et al. · Science Translational Medicine Open access 9 Oct 2019 865
14 CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells Paul Andrew Antony, Ciriaco A. Piccirillo, Akgül Akpınarlı et al. · The Journal of Immunology Open access Mar 2005 754
15 MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study Paolo A. Ascierto, Dirk Schadendorf, Carola Berking et al. · The Lancet Oncology 12 Feb 2013 647
16 Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial Adrianus Johannes De Langen et al. · The Lancet Open access 7 Feb 2023 609
17 Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial Ben J. Slotman, Harm van Tinteren, John O. Praag et al. · The Lancet Open access 15 Sep 2014 607
18 Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer Ryan Bruce Corcoran et al. · Cancer Discovery Open access 8 Feb 2018 599
19 Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial Penella J. Woll, Peter Reichardt, Axel Le Cesne et al. · The Lancet Oncology 3 Sep 2012 596
20 Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice Paul Krimpenfort, Kim C. Quon, Wolter J. Mooi et al. · Nature Sep 2001 594
21 Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial Amit M. Oza, David Cibula, Ana Oaknin Benzaquen et al. · The Lancet Oncology 3 Dec 2014 554
22 Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. Nico J. Stam, Hergen Spits, Hidde L. Ploegh · The Journal of Immunology Oct 1986 547
23 Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab Alexander Martens et al. · Clinical Cancer Research Open access 19 Jan 2016 546
24 Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial Thomas Powles et al. · The Lancet Oncology Open access227 authors 21 Sep 2020 509
25 Physical Activity and Breast Cancer Evelyn M. Monninkhof, Sjoerd Geert Elias, Femke A. Vlems et al. · Epidemiology 22 Nov 2006 504
26 Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial Evan W. Alley, Juanita Suzanne Lopez, Armando Santoro et al. · The Lancet Oncology 10 Mar 2017 493
27 Mesothelioma: Scientific clues for prevention, diagnosis, and therapy Michele Carbone et al. · CA A Cancer Journal for Clinicians Open access 8 Jul 2019 464
28 Isolated Limb Perfusion with Tumor Necrosis Factor and Melphalan for Limb Salvage in 186 Patients with Locally Advanced Soft Tissue Extremity Sarcomas Alexander M.M. Eggermont, Heimen Schraffordt Koops, Joseph M. Klausner et al. · Annals of Surgery Open access Dec 1996 460
29 Pancreatic cancer Thomas F. Stoop, Ammar A. Javed, Atsushi Oba et al. · The Lancet Open access Apr 2025 452
30 Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes José M. C. Tubío et al. · Science Open access 31 Jul 2014 446
31 Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Consensus Statement Jesús Esquivel et al. · Annals of Surgical Oncology 27 Oct 2006 433
32 Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial Joaquim Bellmunt et al. · The Lancet Oncology Open access 14 Mar 2021 431
33 The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer Andrew Gordon Nicholson et al. · Journal of Thoracic Oncology Open access152 authors 24 Dec 2015 429
34 Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial Andres M. Poveda et al. · The Lancet Oncology Open access123 authors 20 Mar 2021 427
35 Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking Linda V. Sinclair, David K. Finlay, Carmen Gloria Feijóo et al. · Nature Immunology Open access 6 Apr 2008 396
36 Federated learning enables big data for rare cancer boundary detection Sarthak Pati et al. · Nature Communications Open access279 authors 5 Dec 2022 390
37 Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer Ulrich Gatzemeier, G. Groth, Charles Andrew Butts et al. · Annals of Oncology Open access 19 Dec 2003 387
38 Mfn2 ubiquitination by PINK1/parkin gates the p97-dependent release of ER from mitochondria to drive mitophagy Gian‐Luca McLelland, Thomas Goiran, Wei Yi et al. · eLife Open access 20 Apr 2018 386
39 Self-Recognition of Cd1 by γ/δ T Cells Franca M. Spada, Ethan P. Grant, Peter J. Peters et al. · The Journal of Experimental Medicine Open access 13 Mar 2000 378
40 Differential Development of Murine Dendritic Cells by GM-CSF versus Flt3 Ligand Has Implications for Inflammation and Trafficking Yuekang Xu, Yifan Zhan, Andrew M. Lew et al. · The Journal of Immunology Dec 2007 375
41 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age Martine J Piccart et al. · The Lancet Oncology Open access 14 Mar 2021 373
42 Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment Fred H. Menko, Eamonn Richard Maher, Laura S. Schmidt et al. · Familial Cancer Open access 10 Jul 2014 368
43 Live Tracking of Inter-organ Communication by Endogenous Exosomes In Vivo Frederik J. Verweij, Céline Revenu, Guillaume Arras et al. · Developmental Cell Open access Feb 2019 352
44 The general public’s information needs and perceptions regarding hereditary cancer: an application of the Integrated Change Model Hein de Vries, Ilse Mesters, Hermanna van de Steeg et al. · Patient Education and Counseling 8 Jun 2004 340
45 An exercise-inducible metabolite that suppresses feeding and obesity Veronica L. Li et al. · Nature Open access 15 Jun 2022 332
46 Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review DAVID M. GILLIGAN, Marianne C. Nicolson, Ian Smith et al. · The Lancet Review Jun 2007 326
47 Primary T Cell Expansion and Differentiation In Vivo Requires Antigen Presentation by B Cells Alison Crawford, Megan K. L. MacLeod, Ton N. Schumacher et al. · The Journal of Immunology Open access Mar 2006 318
48 Translation procedures for standardised quality of life questionnaires: The European Organisation for Research and Treatment of Cancer (EORTC) approach Michael T Koller, Neil K. Aaronson, Jane M. Blazeby et al. · European Journal of Cancer Aug 2007 304
49 Consensus Guidelines for the Management of Patients with Liver Metastases from Digestive (Neuro)endocrine Tumors: Foregut, Midgut, Hindgut, and Unknown Primary Thomas Steinmüller, Réza Kianmanesh, Massimo Falconi et al. · Neuroendocrinology Open access 21 Nov 2007 296
50 Correcting for Lead Time and Length Bias in Estimating the Effect of Screen Detection on Cancer Survival Stephen William Duffy, Irıs D. Nagtegaal, Matthew Wallis et al. · American Journal of Epidemiology 13 May 2008 290

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.